CPM抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Human kidney tissue, HT-29 and 293T cell lysates, Primary antibody: P09434(CPM Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

The CPM antibody targets carboxypeptidase M (CPM), a membrane-bound glycoprotein belonging to the metallocarboxypeptidase family. CPM is anchored to the cell membrane via glycosylphosphatidylinositol (GPI) and plays a regulatory role in peptide hormone processing, inflammation, and cellular signaling. It specifically cleaves C-terminal basic residues (arginine or lysine) from peptides, modulating the activity of substrates like bradykinin, endothelin-1. and anaphylatoxins (e.g., C3a, C5a), thereby influencing blood pressure regulation, immune responses, and tissue remodeling.

CPM is widely expressed in tissues, including the lungs, kidneys, and placenta, and is implicated in pathological conditions such as cancer, fibrosis, and inflammatory diseases. In oncology, elevated CPM levels correlate with tumor progression and metastasis, likely due to its role in extracellular matrix remodeling and growth factor activation. Research using CPM antibodies has helped elucidate its involvement in these processes, highlighting its potential as a diagnostic biomarker or therapeutic target. Antibodies against CPM enable detection, localization, and functional studies in both normal and diseased states, contributing to drug development and mechanistic understanding of its biological pathways. Their applications span immunohistochemistry, Western blotting, and flow cytometry, supporting both basic research and clinical investigations.